Abcuro, Inc logo

Abcuro, Inc

Developing immunotherapies for autoimmune diseases and cancer

43 employees · est. 2015

VS
Mersana Therapeutics logo

Mersana Therapeutics

Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer.

159 employees · est. 2001 · Cambridge, United States

Mersana Therapeutics is the older company (2015 vs 2001); Mersana Therapeutics is the larger of the two.

Side-by-Side Comparison

Abcuro, Inc Mersana Therapeutics
Founded
2015 2001 older
Headquarters
Not tracked yet Cambridge, United States
Employees
43 159 larger
Industry
Biotechnology, Health Care, Health and Wellness Biotechnology, Health Care, Health and Wellness
Funding Stage
Series B Acquired
Total Funding
$214.85M $534.80M
Funding Rounds
5 13
Services
Not tracked yet Drug Development, Clinical Trials, Patient Resource Support
Target Customers
Not tracked yet Patients with cancer, Healthcare providers, Pharmaceutical partners, Researchers
Taxonomy
Immunotherapy, Autoimmune Diseases, Cancer Treatments, Clinical Stage, Anti-KLRG1 Antibody, Orphan Drug Designation, Tumor Microenvironment, Bioinformatics, Transcriptome Analysis, Immune-modulatory Bio-therapeutics, Target Validation, Clinical Insights, Cytotoxic T Cells, NK Cells Antibody-Drug Conjugates (ADCs), Cancer Research, Oncology Drug Development, Bioconjugation, Cytotoxic Therapeutics, Immunostimulatory Therapeutics, Biodegradable Polymer Platform, B7-H4 Targeting, HER2 Targeting, Clinical-Stage Biopharmaceuticals
Website
abcuro.com mersana.com
Abcuro, Inc logo

About Abcuro, Inc

Abcuro, Inc is a clinical stage biotechnology company founded in 2015 that focuses on developing immunotherapies for autoimmune diseases and cancer. The company is known for its flagship products ABC008 and ABC015, both of which target cytotoxic T and NK cells expressing the inhibitory immune checkp...

Mersana Therapeutics logo

About Mersana Therapeutics

Mersana Therapeutics, founded in 2001, is a visionary player in the Biotechnology and Health Care sectors, headquartered in the United States. With its mission, "Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer," the company stands at...

We will tell you when either one moves

BounceWatch watches Abcuro, Inc and Mersana Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Abcuro, Inc and Mersana Therapeutics — by email.

Frequently Asked Questions

Abcuro, Inc — Developing immunotherapies for autoimmune diseases and cancer. Mersana Therapeutics — Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Abcuro, Inc has raised $214.85M while Mersana Therapeutics has raised $534.80M.
Abcuro, Inc and Mersana Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Abcuro, Inc with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Abcuro, Inc on 11 Sep 2024, and Mersana Therapeutics on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy